

Resource Summary Report

Generated by [RRID](#) on Aug 26, 2026

pHR_Gal4UAS_tBFP_PGK_mCherry

RRID:Addgene_79130

Type: Plasmid

Proper Citation

RRID:Addgene_79130

Plasmid Information

URL: <http://www.addgene.org/79130>

Proper Citation: RRID:Addgene_79130

Insert Name: tBFP

Organism: Synthetic

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:26830878](#)

Vector Backbone Description: Vector Backbone:pHR; Vector Types:Lentiviral; Bacterial Resistance:Ampicillin

Comments: Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits. Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, Lim WA. Cell. 2016 Feb 11;164(4):770-9. Epub 2016 Jan 28.

Plasmid Name: pHR_Gal4UAS_tBFP_PGK_mCherry

Record Creation Time: 20220422T222520+0000

Record Last Update: 20260815T082029+0000

Ratings and Alerts

No rating or validation information has been found for pHR_Gal4UAS_tBFP_PGK_mCherry.

No alerts have been found for pHR_Gal4UAS_tBFP_PGK_mCherry.

Data and Source Information

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chen X, et al. (2026) Programmable macromolecule delivery via engineered trogocytosis. *Nature cell biology*, 28(5), 1076.

Sun S, et al. (2025) Preclinical evaluation of antitumor activity and toxicity of TROP2-specific CAR-T cells for treatment of triple-negative breast cancer. *Journal for immunotherapy of cancer*, 13(9).

Vogt KC, et al. (2025) Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity. *Science advances*, 11(4), eads3403.

Goyette MA, et al. (2024) Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies. *Proceedings of the National Academy of Sciences of the United States of America*, 121(20), e2322688121.

Yaman S, et al. (2024) Targeted chemotherapy via HER2-based chimeric antigen receptor (CAR) engineered T-cell membrane coated polymeric nanoparticles. *Bioactive materials*, 34, 422.

Cortese M, et al. (2024) Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification. *Molecular therapy : the journal of the American Society of Gene Therapy*, 32(8), 2741.

Ruffo E, et al. (2023) Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting. *Nature communications*, 14(1), 2463.

Zhu I, et al. (2022) Modular design of synthetic receptors for programmed gene regulation in cell therapies. *Cell*, 185(8), 1431.

Moghimi B, et al. (2021) Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. *Nature communications*, 12(1), 511.

Dannenfelser R, et al. (2020) Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies. *Cell systems*, 11(3), 215.

Foight GW, et al. (2019) Multi-input chemical control of protein dimerization for programming graded cellular responses. *Nature biotechnology*, 37(10), 1209.

Allen ME, et al. (2019) An AND-Gated Drug and Photoactivatable Cre-loxP System for Spatiotemporal Control in Cell-Based Therapeutics. *ACS synthetic biology*, 8(10), 2359.

Roybal KT, et al. (2016) Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. *Cell*, 167(2), 419.